The analysts at Deutsche Bank regard the news for the second quarter as fairly uneventful, and the numbers are rated as rather insignificant. In addition, there was no conference call for analysts as a result, and the company has not yet issued any annual forecasts.
The company still has over 500 million euros in cash, which provides some peace of mind. The acquisition of the oncology bioinformatics platform Frame for EUR 34 million is being praised. From the point of view of the experts, this makes sense.
On the other hand, one does not want to comment on the legal dispute between Curevac and BioNTech, one has no real opinion on this.
The analysts continue to issue a hold recommendation for Curevac shares. The experts continue to see the price target at $20.00.
At noon, the Curevac shares (WKN: A2P71U, ISIN: NL0015436031, Chart ) gain 0.7 percent to 9.534 euros.